Why one potassium channel matters so much
Every heartbeat ends with the heart muscle cells resetting their electrical charge so they are ready to fire again. A potassium ion channel encoded by a gene called hERG does much of that resetting. Block it and the reset is delayed; on an ECG this shows up as a longer gap called QT prolongation. In the worst case that delay triggers a chaotic, sometimes fatal arrhythmia. This is the dominant mechanism of small-molecule cardiotoxicity, and regulators take it extremely seriously.
What makes hERG inhibition uniquely dangerous is how *promiscuous* the channel is. Its inner pore is large, greasy, and lined with aromatic residues, so it happily traps a huge range of drug-like molecules. Antihistamines, antipsychotics, and antibiotics have all been pulled from the market or restricted because of it. The channel does not care what disease you are treating — if your molecule has the wrong shape, it fits.
The hERG pharmacophore: what the channel loves
Three molecular features push a compound toward hERG binding, and you should learn to see them at a glance. First, high [[lipophilicity|lipophilicity]] — greasy molecules partition happily into that greasy pore. Second, a basic centre: a nitrogen that is positively charged at body pH (a high pKa) makes a strong cation–π attraction to the channel's aromatic residues. Third, flat aromatic surface area that stacks against those same residues. A lipophilic molecule with a basic amine and a couple of flat rings is almost a portrait of a hERG blocker.
Concrete moves to lower hERG
- Lower lipophilicity. Trim a greasy substituent or add a polar group. Dropping logD is the single most reliable lever, and it helps solubility and clearance too.
- Tame the basic centre. Lower the amine's pKa by putting an electron-withdrawing group nearby, or replace the basic nitrogen with a neutral bioisostere. Less positive charge means a weaker cation–π grip on the channel.
- Break up the flatness. Add an out-of-plane substituent or a small ring to introduce three-dimensional bulk; the greasy pore tolerates flat shapes far better than chunky ones.
- Build a clean [[structure-activity-relationship|SAR]] against hERG. Test analogues in a dedicated hERG assay alongside your potency assay, so you can read the selectivity between target and channel directly and steer toward a safe margin.
The goal is rarely zero hERG activity — it is a comfortable gap between the concentration that blocks the channel and the concentration your drug reaches in the body. A common rule of thumb asks for the hERG block to sit at least ~30-fold above the free plasma concentration. The wider that ratio, the more peacefully you sleep.